NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis
NYSE:NMR - New York Stock Exchange, Inc. - US65535H2085 - ADR - Currency: USD
Overall NMR gets a fundamental rating of 3 out of 10. We evaluated NMR against 225 industry peers in the Capital Markets industry. NMR may be in some trouble as it scores bad on both profitability and health. NMR is not valued too expensively and it also shows a decent growth rate. NMR also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
NMR had positive earnings in the past year.
In the past year NMR has reported a negative cash flow from operations.
NMR had positive earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: NMR reported negative operating cash flow in multiple years.
1.2 Ratios
NMR's Return On Assets of 0.48% is on the low side compared to the rest of the industry. NMR is outperformed by 73.52% of its industry peers.
With a Return On Equity value of 8.32%, NMR perfoms like the industry average, outperforming 47.03% of the companies in the same industry.
The Return On Invested Capital of NMR (0.49%) is worse than 73.52% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for NMR is significantly below the industry average of 6.76%.
The 3 year average ROIC (0.31%) for NMR is below the current ROIC(0.49%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.48% | ||
| ROE | 8.32% | ||
| ROIC | 0.49% |
ROA(3y)0.27%
ROA(5y)0.34%
ROE(3y)4.27%
ROE(5y)5.33%
ROIC(3y)0.31%
ROIC(5y)0.34%
1.3 Margins
Looking at the Profit Margin, with a value of 5.83%, NMR is doing worse than 68.49% of the companies in the same industry.
NMR's Profit Margin has declined in the last couple of years.
NMR has a Operating Margin of 8.63%. This is in the lower half of the industry: NMR underperforms 71.69% of its industry peers.
NMR's Operating Margin has declined in the last couple of years.
The Gross Margin of NMR (37.85%) is worse than 68.49% of its industry peers.
NMR's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.63% | ||
| PM (TTM) | 5.83% | ||
| GM | 37.85% |
OM growth 3Y-22.7%
OM growth 5YN/A
PM growth 3Y-25.03%
PM growth 5YN/A
GM growth 3Y-24.32%
GM growth 5Y-9.19%
2. Health
2.1 Basic Checks
Compared to 1 year ago, NMR has less shares outstanding
Compared to 5 years ago, NMR has less shares outstanding
NMR has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -0.29, we must say that NMR is in the distress zone and has some risk of bankruptcy.
NMR has a worse Altman-Z score (-0.29) than 83.56% of its industry peers.
A Debt/Equity ratio of 11.22 is on the high side and indicates that NMR has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 11.22, NMR is doing worse than 91.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 11.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.29 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
NMR has a Current Ratio of 0.23. This is a bad value and indicates that NMR is not financially healthy enough and could expect problems in meeting its short term obligations.
NMR has a worse Current ratio (0.23) than 87.67% of its industry peers.
A Quick Ratio of 0.23 indicates that NMR may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.23, NMR is doing worse than 87.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.23 | ||
| Quick Ratio | 0.23 |
3. Growth
3.1 Past
The earnings per share for NMR have decreased strongly by -33.89% in the last year.
NMR shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.34% yearly.
The Revenue has grown by 56.01% in the past year. This is a very strong growth!
The Revenue has been growing slightly by 4.75% on average over the past years.
EPS 1Y (TTM)-33.89%
EPS 3Y-23.06%
EPS 5Y-13.34%
EPS Q2Q%106.53%
Revenue 1Y (TTM)56.01%
Revenue growth 3Y8.4%
Revenue growth 5Y4.75%
Sales Q2Q%10.99%
3.2 Future
Based on estimates for the next years, NMR will show a very strong growth in Earnings Per Share. The EPS will grow by 34.10% on average per year.
Based on estimates for the next years, NMR will show a quite strong growth in Revenue. The Revenue will grow by 10.07% on average per year.
EPS Next Y78.95%
EPS Next 2Y80.72%
EPS Next 3Y46.76%
EPS Next 5Y34.1%
Revenue Next Year0.68%
Revenue Next 2Y21.92%
Revenue Next 3Y13.45%
Revenue Next 5Y10.07%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 30.86, which means the current valuation is very expensive for NMR.
Based on the Price/Earnings ratio, NMR is valued a bit more expensive than 73.97% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 29.63. NMR is around the same levels.
A Price/Forward Earnings ratio of 9.36 indicates a reasonable valuation of NMR.
73.52% of the companies in the same industry are more expensive than NMR, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.68, NMR is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.86 | ||
| Fwd PE | 9.36 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NMR is valued a bit cheaper than the industry average as 69.86% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 23.76 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NMR's earnings are expected to grow with 46.76% in the coming years.
PEG (NY)0.39
PEG (5Y)N/A
EPS Next 2Y80.72%
EPS Next 3Y46.76%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 5.36%, NMR is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 10.00, NMR has a dividend in line with its industry peers.
NMR's Dividend Yield is rather good when compared to the S&P500 average which is at 2.29.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.36% |
5.2 History
On average, the dividend of NMR grows each year by 7.29%, which is quite nice.
NMR has paid a dividend for at least 10 years, which is a reliable track record.
NMR has decreased its dividend in the last 3 years.
Dividend Growth(5Y)7.29%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
NMR pays out 25.01% of its income as dividend. This is a sustainable payout ratio.
The dividend of NMR is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.01%
EPS Next 2Y80.72%
EPS Next 3Y46.76%
6.48
-0.14 (-2.11%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners36.33%
Inst Owner Change4.7%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.15B
Analysts69.23
Price Target6.69 (3.24%)
Short Float %0.02%
Short Ratio1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.36% |
Yearly Dividend20.14
Dividend Growth(5Y)7.29%
DP25.01%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.29%
PT rev (3m)12.29%
EPS NQ rev (1m)23.59%
EPS NQ rev (3m)N/A
EPS NY rev (1m)16.86%
EPS NY rev (3m)15.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1.11%
Revenue NY rev (3m)27.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.86 | ||
| Fwd PE | 9.36 | ||
| P/S | 0.61 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.87 | ||
| P/tB | 0.88 | ||
| EV/EBITDA | 23.76 |
EPS(TTM)0.21
EY3.24%
EPS(NY)0.69
Fwd EY10.68%
FCF(TTM)-2.88
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS10.63
BVpS7.45
TBVpS7.38
PEG (NY)0.39
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.48% | ||
| ROE | 8.32% | ||
| ROCE | 1.45% | ||
| ROIC | 0.49% | ||
| ROICexc | 0.54% | ||
| ROICexgc | 0.55% | ||
| OM | 8.63% | ||
| PM (TTM) | 5.83% | ||
| GM | 37.85% | ||
| FCFM | N/A |
ROA(3y)0.27%
ROA(5y)0.34%
ROE(3y)4.27%
ROE(5y)5.33%
ROIC(3y)0.31%
ROIC(5y)0.34%
ROICexc(3y)0.34%
ROICexc(5y)0.37%
ROICexgc(3y)0.34%
ROICexgc(5y)0.38%
ROCE(3y)0.89%
ROCE(5y)1.01%
ROICexcg growth 3Y-3.29%
ROICexcg growth 5YN/A
ROICexc growth 3Y-3.32%
ROICexc growth 5YN/A
OM growth 3Y-22.7%
OM growth 5YN/A
PM growth 3Y-25.03%
PM growth 5YN/A
GM growth 3Y-24.32%
GM growth 5Y-9.19%
F-Score5
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 11.22 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 78.89 | ||
| Cap/Depr | 1824.53% | ||
| Cap/Sales | 24.27% | ||
| Interest Coverage | 0.14 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.23 | ||
| Quick Ratio | 0.23 | ||
| Altman-Z | -0.29 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)580.51%
Cap/Depr(5y)450.89%
Cap/Sales(3y)10.9%
Cap/Sales(5y)10.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.89%
EPS 3Y-23.06%
EPS 5Y-13.34%
EPS Q2Q%106.53%
EPS Next Y78.95%
EPS Next 2Y80.72%
EPS Next 3Y46.76%
EPS Next 5Y34.1%
Revenue 1Y (TTM)56.01%
Revenue growth 3Y8.4%
Revenue growth 5Y4.75%
Sales Q2Q%10.99%
Revenue Next Year0.68%
Revenue Next 2Y21.92%
Revenue Next 3Y13.45%
Revenue Next 5Y10.07%
EBIT growth 1Y94.33%
EBIT growth 3Y5.89%
EBIT growth 5YN/A
EBIT Next Year33905.4%
EBIT Next 3Y608.28%
EBIT Next 5YN/A
FCF growth 1Y33.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y92.55%
OCF growth 3Y-49.33%
OCF growth 5YN/A